The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

Arancha Prada-Villaverde, Jesus Esquivel, Andrew M. Lowy, Maurie Markman, Terence Chua, Joerg Pelz, Dario Baratti, Joel M. Baumgartner, Richard Berri, Pedro Bretcha-Boix, Marcello Deraco, Guillermo Flores-Ayala, Olivier Glehen, Alberto Gomez-Portilla, Santiago González-Moreno, Martin Goodman, Evgenia Halkia, Shigeki Kusamura, Mecker Moller, Guillaume PassotMarc Pocard, George Salti, Armando Sardi, Maheswari Senthil, John Spiliotis, Juan Torres-Melero, Kiran Turaga, Richard Trout

Research output: Contribution to journalArticle

Abstract

Background Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are gaining acceptance as treatment for selected patients with colorectal cancer with peritoneal carcinomatosis (CRCPC). Tremendous variations exist in the HIPEC delivery. Methods The American Society of Peritoneal Surface Malignancies (ASPSM) examined the overall survival in patients with CRCPC who underwent a complete cytoreduction and HIPEC with Oxaliplatin vs. Mitomycin C (MMC), stratifying them by the Peritoneal Surface Disease Severity Score (PSDSS). Results Median overall survival (OS) of 539 patients with complete cytoreduction was 32.6 months, 32.7 months for the MMC group and 31.4 months for the Oxaliplatin group (P=0.925). However, when stratified by PSDSS, median OS rates in PSDSS I/II patients were 54.3 months in those receiving MMC vs. 28.2 months in those receiving oxaliplatin (P=0.012), whereas in PSDSS III/IV patients, median OS rates were 19.4 months in those receiving MMC vs. 30.4 months in those receiving Oxaliplatin (P=0.427). Conclusion These data suggest that MMC might be a better agent for HIPEC delivery than Oxaliplatin in patients with CRCPC, favorable histologies and low burden of disease (PSDSS I/II) undergoing complete cytoreduction. Propsective studies are warranted, which stratify patients by their PSDSS and randomize them to HIPEC with MMC vs. Oxaliplatin. J. Surg. Oncol. 2014 110:779-785.

Original languageEnglish
Pages (from-to)779-785
Number of pages7
JournalJournal of Surgical Oncology
Volume110
Issue number7
DOIs
Publication statusPublished - Dec 1 2014

Keywords

  • colorectal cancer with peritoneal carcinomatosis
  • cytoreductive surgery
  • hyperthermic intraperitoneal chemotherapy (HIPEC)

ASJC Scopus subject areas

  • Surgery
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery'. Together they form a unique fingerprint.

  • Cite this

    Prada-Villaverde, A., Esquivel, J., Lowy, A. M., Markman, M., Chua, T., Pelz, J., Baratti, D., Baumgartner, J. M., Berri, R., Bretcha-Boix, P., Deraco, M., Flores-Ayala, G., Glehen, O., Gomez-Portilla, A., González-Moreno, S., Goodman, M., Halkia, E., Kusamura, S., Moller, M., ... Trout, R. (2014). The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Journal of Surgical Oncology, 110(7), 779-785. https://doi.org/10.1002/jso.23728